Legal & General Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $711K | Buy |
62,420
+3,801
| +6% | +$43.3K | ﹤0.01% | 2339 |
|
|
2025
Q1 | $696K | Sell |
58,619
-1,798
| -3% | -$21.4K | ﹤0.01% | 2300 |
|
|
2024
Q4 | $1.14M | Buy |
60,417
+518
| +0.9% | +$9.76K | ﹤0.01% | 2194 |
|
|
2024
Q3 | $1.35M | Buy |
59,899
+9,019
| +18% | +$203K | ﹤0.01% | 2124 |
|
|
2024
Q2 | $1.06M | Buy |
50,880
+44,138
| +655% | +$921K | ﹤0.01% | 2177 |
|
|
2024
Q1 | $99.1K | Sell |
6,742
-154
| -2% | -$2.26K | ﹤0.01% | 2738 |
|
|
2023
Q4 | $71.2K | Sell |
6,896
-25,083
| -78% | -$259K | ﹤0.01% | 2776 |
|
|
2023
Q3 | $251K | Sell |
31,979
-559
| -2% | -$4.39K | ﹤0.01% | 2668 |
|
|
2023
Q2 | $325K | Buy |
32,538
+17,932
| +123% | +$179K | ﹤0.01% | 2603 |
|
|
2023
Q1 | $130K | Buy |
14,606
+610
| +4% | +$5.42K | ﹤0.01% | 2721 |
|
|
2022
Q4 | $154K | Buy |
13,996
+717
| +5% | +$7.87K | ﹤0.01% | 2702 |
|
|
2022
Q3 | $173K | Buy |
13,279
+1,106
| +9% | +$14.4K | ﹤0.01% | 2675 |
|
|
2022
Q2 | $154K | Buy |
12,173
+3,216
| +36% | +$40.7K | ﹤0.01% | 2731 |
|
|
2022
Q1 | $126K | Sell |
8,957
-10
| -0.1% | -$141 | ﹤0.01% | 2807 |
|
|
2021
Q4 | $259K | Buy |
8,967
+53
| +0.6% | +$1.53K | ﹤0.01% | 2609 |
|
|
2021
Q3 | $267K | Buy |
8,914
+5,241
| +143% | +$157K | ﹤0.01% | 2597 |
|
|
2021
Q2 | $98K | Buy |
3,673
+747
| +26% | +$19.9K | ﹤0.01% | 2743 |
|
|
2021
Q1 | $90K | Buy |
2,926
+1,248
| +74% | +$38.4K | ﹤0.01% | 2647 |
|
|
2020
Q4 | $55K | Buy |
1,678
+434
| +35% | +$14.2K | ﹤0.01% | 2772 |
|
|
2020
Q3 | $43K | Buy |
+1,244
| New | +$43K | ﹤0.01% | 2746 |
|